Recent events
Recent events tied to this brand in public sources.
Back to profile15 entries
2027
Boston Scientific appoints Joe Fitzgerald as EVP and Chief Operating Officer, effective 1 January 2027
Boston Scientific appointed Joe Fitzgerald as its next Executive Vice President and Chief Operating Officer, effective 1 January 2027, re-establishing the COO position. Fitzgerald, currently EVP of the Cardiovascular division, will oversee global operations, commercial business units and regions as the medtech manufacturer pursues international expansion.
2026
Boston Scientific restructures operating model into three reportable clinical segments
Boston Scientific announced a restructuring of its operating model into three reportable segments — Interventional Therapies under Lance Bates, Rhythm Solutions under Nick Spadea-Anello and MedSurg under Stephen Morse — shifting from product-centric business units to a model aligned with clinical delivery pathways, while consolidating investments as it targets US$500m in annual run-rate cost savings by the end of 2029.
2026
FDA classifies Boston Scientific ENROUTE device recall as Class I
The FDA classified a recall of certain Boston Scientific ENROUTE Transcarotid Neuroprotection System and ENROUTE NPS Plus devices as Class I, the most serious type, following reports of arterial sheath tip separation during use. Boston Scientific had sent the initial letter to affected customers on July 9, 2026.
2026
Boston Scientific discloses cyberattack disrupting global operations and shipments
Boston Scientific disclosed on Wednesday that a cyberattack detected the previous day is disrupting its global operations, including its ability to process and ship customer orders.
2026
Boston Scientific discloses cyberattack disrupting global operations
Boston Scientific said on Wednesday that a cyberattack affecting some of its information-technology systems has caused global disruptions and limited access to certain information systems and business applications supporting its operations, including its ability to process and ship customer orders. The company said it does not yet know the full scope and nature of the breach, including operational and financial impacts, and is working with cybersecurity experts to assess and contain the threat and restore affected systems, without a timeline for full restoration.
2026
Boston Scientific discloses cybersecurity incident disrupting global operations
Boston Scientific said on Wednesday that a cybersecurity incident detected on August 25 disrupted global operations, including some information systems used to process and ship customer orders. The company activated incident-response procedures and is working with third-party cybersecurity specialists to investigate and contain the threat; it said the full scope and nature of the incident have not yet been determined and it has not determined whether the incident is reasonably likely to have a material impact on its business.
2022
Boston Scientific finalizes Baylis Medical acquisition
Boston Scientific finalized its acquisition of Quebec-based Baylis Medical Co. Inc. on Tuesday.
2021
Jury finds Nevro infringed two Boston Scientific patents
A Delaware jury found that Nevro infringed two Boston Scientific patents and awarded Boston Scientific $20 million. Nevro said it disagreed with the finding and planned to appeal.
2021
Boston Scientific elects David Wichmann to its board
Boston Scientific announced that David Wichmann had been elected to its board of directors, effective immediately.
2021
FDA approves Boston Scientific Vercise Genus system
The FDA approved Boston Scientific’s fourth-generation Vercise Genus Deep Brain Stimulation System. The system is intended to provide symptom relief for Parkinson’s disease.
2020
Nevro and Boston Scientific agree to dismiss California patent case
Nevro and Boston Scientific agreed to dismiss the remaining claims in Nevro's California patent case concerning high-frequency spinal cord stimulation therapy. The dismissal remained subject to court approval; the parties said other patent cases would continue.
2020
Boston Scientific signs exclusive equity acquisition agreement with Farapulse
Boston Scientific announced that it had signed an investment agreement with Farapulse for an exclusive equity acquisition.
2020
Vercise Genus system receives CE Mark
Boston Scientific announced that its Vercise Genus Deep Brain Stimulation System had received CE Mark for the European market.
2020
Boston Scientific announces APAC leadership succession
Boston Scientific announced that APAC president Wang Xin was set to leave and that Art Butcher would take over the role in February and be based in Singapore.
2020
Boston Scientific announces preliminary 2019 sales
Boston Scientific announced preliminary unaudited sales of approximately $2.90 billion for the fourth quarter of 2019 and approximately $10.74 billion for full-year 2019. The company said the information was preliminary and subject to completion of year-end reporting processes, reviews, and audit.